말초혈관 디바이스 시장 예측(2026-2032년)

The Peripheral Vascular Devices Market is projected to grow by USD 16.60 billion at a CAGR of 8.06% by 2032.

Peripheral Vascular Devices Executive Summary

Peripheral vascular devices are critical tools used to diagnose and treat peripheral artery disease, venous thromboembolism, aneurysms, arteriovenous access complications, and other vascular conditions outside the heart and brain. Demand is supported by well-established clinical and public health drivers, including population aging, diabetes, obesity, smoking exposure, chronic kidney disease, and rising diagnosis of atherosclerotic vascular disease. Global health authorities identify cardiovascular disease as the leading cause of death worldwide, while published epidemiological studies report that peripheral artery disease affects hundreds of millions of people globally, creating a durable clinical need for angioplasty balloons, peripheral stents, atherectomy systems, thrombectomy devices, embolic protection devices, vena cava filters, vascular grafts, and endovascular aneurysm repair technologies.

The sector is moving toward less invasive, image-guided, and patient-specific vascular care. Hospitals, ambulatory surgical centers, and specialized vascular centers increasingly prioritize devices that improve vessel patency, reduce restenosis, shorten procedure times, enable limb salvage, and support same-day or reduced-stay care pathways. At the same time, regulatory expectations, post-market surveillance, device traceability, and clinical evidence generation are becoming more rigorous, especially for drug-coated devices, implantable stents, and long-term vascular implants. For industry participants, success increasingly depends on clinical differentiation, physician training, reimbursement alignment, supply chain reliability, and evidence that devices improve outcomes in real-world vascular populations.

Transformative Shifts in the Peripheral Vascular Devices Landscape

The peripheral vascular devices landscape is being reshaped by the transition from open surgery to endovascular intervention, supported by advances in catheter-based delivery, intravascular imaging, low-profile device platforms, drug-eluting technologies, and hybrid operating environments. Treatment strategies are becoming more lesion-specific, with device selection influenced by vessel size, calcification, lesion length, thrombus burden, below-the-knee anatomy, and comorbidities such as diabetes and renal disease.

A major transformative shift is the growing emphasis on limb preservation and early intervention for peripheral artery disease. Clinical pathways increasingly integrate vascular imaging, wound care, diabetic foot management, and revascularization planning to reduce major amputations. Device innovation is also focusing on complex disease segments, including chronic total occlusions, heavily calcified vessels, venous obstruction, dialysis access maintenance, and endovascular repair of peripheral aneurysms.

Regulatory and clinical scrutiny is also changing product development. Drug-coated balloons and drug-eluting stents remain important technologies, but long-term safety data, patient-level evidence, and transparent adverse event monitoring are now central to adoption decisions. Hospitals are also evaluating total episode-of-care impact, including device durability, reintervention rates, contrast use, radiation exposure, and procedure efficiency. These shifts favor manufacturers and care providers that can combine high-quality clinical data with practical workflow integration and physician education.

Cumulative Impact of AI on Peripheral Vascular Devices

Artificial intelligence is beginning to influence peripheral vascular care across diagnosis, planning, procedure support, and follow-up. AI-enabled imaging tools can assist clinicians in segmenting vessels, quantifying stenosis, identifying calcification patterns, and improving consistency in interpretation across computed tomography angiography, magnetic resonance angiography, duplex ultrasound, and intraprocedural imaging. These capabilities are particularly relevant in peripheral artery disease, where lesion morphology and vessel runoff strongly affect treatment strategy.

In procedural environments, AI has the potential to support device sizing, access planning, navigation, radiation reduction, and contrast optimization. Predictive analytics may help stratify patients by risk of restenosis, thrombosis, wound non-healing, or reintervention, enabling more personalized follow-up schedules and therapy decisions. AI can also strengthen post-market surveillance by detecting device-related safety signals from registries, electronic health records, and real-world evidence databases.

However, cumulative impact depends on validated clinical performance, data quality, interoperability, cybersecurity, and equitable representation of diverse patient populations. AI systems used in vascular care must be evaluated against clinically meaningful endpoints such as diagnostic accuracy, procedural efficiency, limb outcomes, adverse event reduction, and durability of revascularization. For device developers, the strongest opportunities lie in combining AI with imaging, robotics, remote monitoring, and evidence generation while maintaining compliance with evolving medical device software regulations.

Key Regional Insights for Peripheral Vascular Devices

Asia-Pacific is becoming increasingly important for peripheral vascular devices due to a large population base, rising diabetes prevalence, aging demographics, and expanding hospital infrastructure across China, India, Japan, South Korea, Australia, and Southeast Asia. The region shows strong need for peripheral artery disease diagnosis, dialysis access management, venous intervention, and minimally invasive vascular procedures, although adoption levels vary by reimbursement maturity, physician training, procurement systems, and access to advanced imaging.

Europe combines advanced vascular care infrastructure with strong regulatory requirements under the European medical device framework. Western European countries have broad access to endovascular treatment, peripheral stents, angioplasty balloons, vascular grafts, and endovascular aneurysm repair systems, while adoption patterns differ across Central and Eastern Europe depending on reimbursement, clinical capacity, and procurement funding. Clinical registries, health technology assessment, and evidence-based purchasing have significant influence on device adoption and post-market follow-up.

North America remains a highly advanced environment for peripheral vascular intervention, supported by established vascular surgery, interventional radiology, and interventional cardiology networks; robust use of endovascular techniques; and structured regulatory oversight. The United States and Canada emphasize clinical evidence, reimbursement documentation, outpatient procedure efficiency, device traceability, and real-world safety monitoring, particularly for implantable and drug-coated technologies.

Latin America shows expanding demand for peripheral vascular devices as urban hospital systems modernize and chronic disease burdens rise. Brazil and Mexico are central to regional adoption, with growth in endovascular capabilities shaped by public-private healthcare differences, procurement processes, specialist availability, and affordability constraints. Across the region, access to complex limb salvage procedures, thrombectomy devices, and advanced vascular imaging remains concentrated in higher-capacity urban centers.

Africa faces a dual challenge of rising noncommunicable vascular disease and uneven access to specialized vascular intervention. Urban referral centers increasingly provide endovascular care, but device availability, diagnostic access, trained specialists, and affordability remain key limitations. The Middle East is investing in tertiary care, vascular centers, and advanced imaging, with demand linked to diabetes, obesity, smoking, and cardiovascular risk factors. GCC countries are particularly active in adopting advanced medical technologies, while access varies across the broader region.

Key Group Insights for Peripheral Vascular Devices

NATO countries span North America and much of Europe, creating a broad environment of advanced healthcare systems, procurement discipline, and regulatory scrutiny. While NATO itself is not a healthcare market structure, member countries commonly share high standards for device quality, supply chain resilience, cybersecurity, emergency preparedness, and continuity of medical technology procurement, all of which are increasingly relevant for peripheral vascular devices used in urgent and elective vascular care.

G7 countries represent mature and evidence-driven environments for peripheral vascular devices, with high procedural sophistication, strong clinical guideline influence, and emphasis on quality outcomes. These countries typically prioritize safety, durability, physician training, reimbursement-supported innovation, and post-market evidence for peripheral stents, drug-coated balloons, vascular grafts, thrombectomy systems, and endovascular repair technologies.

BRICS countries reflect diverse but clinically significant demand drivers. China and India have large patient pools and expanding vascular infrastructure, Brazil has a growing endovascular base, Russia maintains demand through major urban centers, and South Africa serves as an important advanced-care hub within the African context. Access differences, pricing pressure, regulatory localization, and public-private healthcare variation influence device strategy across the group.

The European Union is shaped by stringent medical device regulation, health technology assessment, and growing demand for real-world clinical evidence. Peripheral vascular device adoption depends heavily on conformity assessment, post-market clinical follow-up, reimbursement rules, registry participation, and demonstrated value in reducing complications, repeat interventions, and long-term vascular care costs.

ASEAN countries are expanding access to peripheral vascular devices through hospital modernization, rising private healthcare participation, and increasing recognition of diabetes-related vascular complications. Adoption is strongest in major urban centers, where endovascular expertise, imaging infrastructure, and international clinical training are more available, while rural access remains uneven and affordability remains central to procurement decisions.

The GCC demonstrates strong potential for advanced vascular technologies due to high healthcare investment, elevated cardiometabolic disease burden, and government initiatives to expand specialized care. Demand is supported by tertiary hospitals and medical city developments, although procurement standardization, local clinical capacity building, and long-term follow-up systems remain important for sustainable adoption.

Key Country Insights for Peripheral Vascular Devices

China is rapidly expanding vascular intervention capacity as its aging population and diabetes burden increase, with policy attention on local manufacturing, hospital modernization, and broader access to advanced devices. The United States is one of the most procedure-intensive environments for peripheral vascular devices, supported by specialized vascular practices, outpatient endovascular centers, advanced reimbursement pathways, and strong use of real-world evidence. Japan has a highly advanced aging-care environment with strong demand for low-profile, precision endovascular technologies and strict quality expectations, while India has substantial unmet need for peripheral artery disease and dialysis access intervention, with adoption concentrated in private and tertiary centers and shaped by affordability.

Germany is a major European center for advanced endovascular practice, supported by hospital capacity, specialist expertise, and rigorous regulatory compliance. The United Kingdom maintains structured vascular networks and guideline-driven care, with strong focus on limb salvage and efficient use of public healthcare resources. Australia combines high clinical standards, centralized reimbursement evaluation, and advanced specialist care, while France combines strong clinical infrastructure with reimbursement evaluation and evidence requirements. South Korea has sophisticated hospital infrastructure, rapid adoption of minimally invasive technologies, and strong digital health readiness, supporting advanced peripheral vascular treatment pathways.

Italy and Spain show significant adoption of minimally invasive vascular procedures across regional health systems, with variation in procurement and access. Canada emphasizes publicly funded care, evidence-based adoption, and regional access planning, with demand driven by aging and chronic disease. Russia has demand concentrated in major metropolitan hospitals, where advanced endovascular capabilities coexist with regional disparities. Brazil leads much of Latin America in vascular procedure capability, with advanced centers in large urban regions and ongoing demand from diabetes, chronic kidney disease, and cardiovascular risk factors. Mexico is expanding vascular intervention capacity in major cities, although access is influenced by payer segmentation and hospital infrastructure.

Actionable Recommendations for Peripheral Vascular Device Leaders

Industry leaders should prioritize clinically differentiated devices that address complex lesions, calcified vessels, below-the-knee disease, venous obstruction, dialysis access, thrombectomy, and long-term implant performance. Product development should be anchored in robust clinical endpoints, including patency, target lesion revascularization, amputation reduction, safety, usability, and quality-of-life outcomes.

Organizations should strengthen real-world evidence capabilities through registries, post-market clinical follow-up, and interoperable data systems that support regulatory compliance and payer confidence. Partnerships with hospitals and physician societies should focus on training, case planning, imaging optimization, and safe adoption of advanced techniques. In emerging markets, strategies should balance affordability, local regulatory requirements, distributor quality, and specialist education.

Supply chain resilience is increasingly important for vascular devices, especially implantable stents, balloons, guidewires, catheters, grafts, and procedure kits. Leaders should also invest in AI-enabled imaging integration, device traceability, cybersecurity, and sustainability in packaging and sterilization. Commercial success will depend on proving value not only through device performance but also through workflow efficiency, reduced complications, and better patient outcomes.

Research Methodology for Peripheral Vascular Devices Analysis

This executive summary is developed through a structured secondary research methodology using verified public-domain and institutionally recognized sources. The approach includes review of clinical guidelines, regulatory communications, public health databases, peer-reviewed literature, disease burden reports, medical device safety updates, reimbursement references, and healthcare infrastructure indicators. Sources typically include national health agencies, international health organizations, regulatory authorities, professional medical societies, clinical registries, and indexed medical publications.

The analysis focuses on qualitative market intelligence rather than market sizing or forecasting. Data points are evaluated for credibility, recency, consistency, and relevance to peripheral vascular devices, including angioplasty balloons, stents, atherectomy systems, thrombectomy devices, embolization devices, vascular grafts, vena cava filters, and endovascular repair systems. Regional, group, and country insights are synthesized by assessing disease burden, healthcare access, regulatory environment, reimbursement maturity, clinical infrastructure, physician expertise, and technology adoption patterns.

To ensure reliability, findings are triangulated across multiple source categories and interpreted in the context of current vascular care pathways. The methodology avoids unsupported claims and does not rely on speculative estimates, market share assumptions, or forward-looking market forecasts.

Conclusion: Advancing Evidence-Based Peripheral Vascular Care

Peripheral vascular devices are positioned at the center of modern vascular care as healthcare systems respond to the growing burden of peripheral artery disease, diabetes-related vascular complications, venous disease, dialysis access challenges, and aneurysmal conditions. The field is advancing through minimally invasive endovascular techniques, improved imaging, drug-based device platforms, complex lesion solutions, and stronger post-market evidence expectations.

Regional adoption differs significantly, with mature healthcare systems emphasizing outcomes, safety, and reimbursement value, while emerging regions focus on access expansion, affordability, infrastructure, and workforce development. Artificial intelligence, real-world evidence, and integrated care pathways are set to play increasingly important roles in diagnosis, procedural planning, surveillance, and patient follow-up.

For stakeholders across the peripheral vascular devices ecosystem, the strategic priority is clear: deliver clinically validated, workflow-compatible, and economically defensible technologies that improve vascular outcomes and expand access to high-quality care. Organizations that align innovation with evidence, training, regulatory rigor, and regional healthcare realities will be best positioned to strengthen their role in the evolving vascular intervention landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Peripheral Vascular Devices Market, by Product

• 7.1. Introduction
• 7.2. Balloon Inflation Devices
• 7.3. Catheters
  • 7.3.1. Long Peripheral Intravenous Catheters
  • 7.3.2. Midline Catheters
  • 7.3.3. Short Peripheral Intravenous Catheter
• 7.4. Grafts
  • 7.4.1. Biological Grafts
  • 7.4.2. ePTFE Grafts
  • 7.4.3. Polyester Grafts
• 7.5. Guidewires
• 7.6. Inferior Vena Cava Filters
• 7.7. Introducers
• 7.8. Plaque Modification Devices
• 7.9. Stents
  • 7.9.1. Balloon-Expandable Stents
  • 7.9.2. Self-Expanding Stents
• 7.10. Vascular Closure Devices

8. Peripheral Vascular Devices Market, by Technology Type

• 8.1. Introduction
• 8.2. Minimally Invasive Surgeries
  • 8.2.1. Angioplasty
  • 8.2.2. Stenting
• 8.3. Open Surgery
  • 8.3.1. Bypass Surgery
  • 8.3.2. Endarterectomy

9. Peripheral Vascular Devices Market, by Material Type

• 9.1. Introduction
• 9.2. Metal Devices
  • 9.2.1. Cobalt Chromium
  • 9.2.2. Nitinol
  • 9.2.3. Stainless Steel
• 9.3. Non-Metal Devices
  • 9.3.1. Polymer
  • 9.3.2. Silicone

10. Peripheral Vascular Devices Market, by Indication

• 10.1. Introduction
• 10.2. Functional Peripheral Vascular Disease
  • 10.2.1. Chronic Venous Insufficiency
  • 10.2.2. Raynaud's Disease
  • 10.2.3. Varicose Veins
• 10.3. Occlusive Peripheral Vascular Disease
  • 10.3.1. Atherosclerosis
  • 10.3.2. Buerger's Disease
  • 10.3.3. Carotid Artery Disease
  • 10.3.4. Deep Vein Thrombosis
  • 10.3.5. Lymphedema

11. Peripheral Vascular Devices Market, by Patient Types

• 11.1. Introduction
• 11.2. Adult & Geriatric
  • 11.2.1. Acute Conditions
  • 11.2.2. Chronic Conditions
• 11.3. Pediatric
  • 11.3.1. Acquired Conditions
  • 11.3.2. Congenital Conditions

12. Peripheral Vascular Devices Market, by End-User

• 12.1. Introduction
• 12.2. Ambulatory Surgical Centers
• 12.3. Clinics
• 12.4. Hospitals

13. Peripheral Vascular Devices Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Latin America
• 13.5. Africa
• 13.6. Middle East

14. Peripheral Vascular Devices Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. BRICS
• 14.4. European Union
• 14.5. ASEAN
• 14.6. GCC

15. Peripheral Vascular Devices Market, by Country

• 15.1. China
• 15.2. United States
• 15.3. Japan
• 15.4. India
• 15.5. Germany
• 15.6. United Kingdom
• 15.7. Australia
• 15.8. France
• 15.9. South Korea
• 15.10. Italy
• 15.11. Canada
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. AngioDynamics, Inc.
• 17.3. Argon Medical Devices, Inc.
• 17.4. ASAHI INTECC CO., LTD
• 17.5. B. Braun SE
• 17.6. Baxter International Inc.
• 17.7. Becton, Dickinson and Company
• 17.8. BIOTRONIK SE & Co. KG
• 17.9. Boston Scientific Corporation
• 17.10. Cardinal Health, Inc.
• 17.11. Cook Group Incorporated
• 17.12. Esaote S.p.A.
• 17.13. FUJIFILM Holdings Corporation
• 17.14. GE HealthCare
• 17.15. Kimal PLC
• 17.16. Koninklijke Philips N.V.
• 17.17. Lepu Medical Technology (Beijing) Co., Ltd.
• 17.18. Medtronic PLC
• 17.19. Merit Medical Systems, Inc.
• 17.20. Nipro Corporation
• 17.21. Penumbra, Inc.
• 17.22. Sahajanand Medical Technologies Limited
• 17.23. Shockwave Medical, Inc. by Johnson & Johnson Services, Inc.
• 17.24. Siemens Healthineers AG
• 17.25. Summa Therapeutics, LLC
• 17.26. Teleflex Incorporated
• 17.27. Terumo Corporation
• 17.28. W. L. Gore & Associates, Inc.